CME: Parkinson’s disease: optimizing pharmacotherapeutic management strategies and addressing clinical challenges
Cost: FreeView Offer chevron_right
Parkinson’s disease (PD), a central nervous system disease of the autonomic and basal ganglia, neocortex, and spinal cord, is thought to affect about one million people in the United States. Its etiology is thought to include a confluence of factors including age, genetic predisposition, comorbid disease states (e.g., Gaucher’s disease), and environmental factor dynamics. Present in 1% of people over age 65 and 2.5% of those older than 80, its symptoms are the direct result of dopaminergic neuronal degradation along the nigrostriatal tract and include bradykinesia, resting tremor, muscle rigidity, and gait disturbance.
By the end of the session the participant will be able to:
- Describe the pathophysiology and disease progression of PD and their impact on patient quality-of-life
- Describe the common clinical presentation(s) of PD
- Apply recent biomedical literature to the management of PD the primary disease, levodopa-related fluctuations in motor function and dyskinesia, and other disease complications and effects impacting quality-of-life
- Identify the advances in the biomedical literature concerning PD and emerging treatment options
- List challenges and barriers to care associated with treating patients with PD
The following healthcare professionals: neurologists and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in neurology; and any other healthcare professionals with an interest in or who clinically encounter patients with PD.